EP Patent

EP4620525A2 — Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Assigned to Respira Therapeutics Inc · Expires 2025-09-24 · 1y expired

What this patent protects

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In s…

USPTO Abstract

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Drugs covered by this patent

Patent Metadata

Patent number
EP4620525A2
Jurisdiction
EP
Classification
—
Expires
2025-09-24
Drug substance claim
No
Drug product claim
No
Assignee
Respira Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.